Back

SGLT2 inhibitor for secondary prevention in acute myocardial infarction patients with diabetes mellitus

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Treatment of acute coronary syndromes in clinical practice Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Dongbin Kim

The Catholic University of Korea, Seoul (Korea (Republic of))

7 More presentations in this session

Presentation thumbnail
Effect of evolocumab on platelet function in patients with acute coronary syndromes. An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial
Doctor K. Koskinas (Bern, CH)
Abstract Slides Video
Presentation thumbnail
ARCANGELO: an observational, prospective study with acute coronary syndrome patients undergoing percutaneous coronary intervention who receive cangrelor transitioning to oral P2Y12 inhibitors
Doctor L. De Luca (Pavia, IT)
Abstract Slides
Presentation thumbnail
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis
Doctor S. Al Said (Boston, US)
Abstract Slides Video
Presentation thumbnail
The effect of sodium-glucose co-transporter-2 inhibitors following anterior ST-segment elevation myocardial infarction
Doctor G. Incesu (Istanbul, TR)
Abstract Slides
Presentation thumbnail
Comparison of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in myocardial infarction patients with type 2 diabetes
Doctor J. Tjerkaski (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment of acute coronary syndromes in clinical practice

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
The association between SGLT2 inhibitors and Incident Dementia in patients with heart failure: A Population-Based Longitudinal Cohort Study
thumbnail
Congress Presentation
Comparison of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in myocardial infarction patients with type 2 diabetes
thumbnail
Congress Presentation
Real-world use of empaglifozin and dapaglifozin in patients with HEART failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources